Identification of cinobufagin metabolites in the bile of rats

Xenobiotica

Volumn 40, Issue 1, 2010, Pages 48-54

  Ning, J ^a   Wu, T H ^a   Tian, Y ^a   Wang, C Y ^a   Tian, G ^a   Zhang, B J ^a   Liu, K X ^a   Ma, X C ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Bufadienolide; Cinobufagin; Hydroxylation; Isomerization; Metabolites

Indexed keywords

12BETA HYDROXY 3 EPI DESACETYLCINOBUFAGIN; 1ALPHA HYDROXY 3 EPI DESACETYLCINOBUFAGIN; 1ALPHA,5ALPHA DIHYDROXY 3 EPI DESACETYLCINOBUFAGIN; 1BETA HYDROXY 3 EPI DESACETYLCINOBUFAGIN; 2ALPHA,5BETA DIHYDROXY 3 EPI DESACETYLCINOBUFAGIN; 3 EPI DESACETYLCINOBUFAGIN; 3 KETODESACETYLCINOBUFAGIN; 5BETA HYDROXY 3 EPI DESACETYLCINOBUFAGIN; CINOBUFAGIN; DESACETYLCINOBUFAGIN; DRUG METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BILE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN HL 60; CONTROLLED STUDY; CYTOTOXICITY; DRUG EXCRETION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HELA CELL; HETERONUCLEAR MULTIPLE BOND CORRELATION; HETERONUCLEAR MULTIPLE QUANTUM COHERENCE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYDROXYLATION; IC 50; IN VITRO STUDY; IN VIVO STUDY; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; ISOMERIZATION; MALE; NONHUMAN; NUCLEAR OVERHAUSER EFFECT; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

ANIMALS; BILE; BUFANOLIDES; CELL SURVIVAL; HELA CELLS; HUMANS; HYDROXYLATION; MEDICINE, CHINESE TRADITIONAL; METABOLIC NETWORKS AND PATHWAYS; RATS;

RATTUS;

EID: 72949113593     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903331049     Document Type: Article

References (24)

1. Arena JM, Drew RH. (1985). Poisoning: Toxicology, symptoms, treatments. 5th ed. Springfield, IL: CharlesC. Thomas.
2. Gilman A, Goodman LS, Rall TW, Murad F. (1985). The pharmacological basis of Therapeutics. 7th ed. New York, NY: Macmillan.
3. Kamano Y, Kotake A, Hashima H, Inoue M, Morita H, Takeya K, Pettit GP. (1998). Structure-cytotoxic activity relationship for the toad poison bufadienolides. Bioorg Med Chem 6:1103-1115. (Pubitemid 28464541)
4. Kamano Y, Yamashita A, Nogawa T, Morita H, Takeya K, Itokawa H, Prttit GR. (2002). QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1). J Med Chem 45:5440-5447.
5. Krenn L, Kopp B. (1998). Bufadienolides from animal and plant sources. Phytochemistry 48:1-4.
6. Ma XC, Cui J, Zheng J, Guo DA. (2007a). Microbial transformation of three bufadienolides by Penicillum aurntigriseum and its application for metabolite identification in rats. J Mol Cataly B Enz. 48:42-50.
7. Ma XC, Xin XL, Liu KX, Han J, Guo DA. (2009a). Microbial transformation of cinobufagin by Syncephalastrum racemosum. J Nat Prod 71:1268-1270.
8. Ma XC, Zhang BJ, Xin XL. (2009b). Simultaneous quantification of seven major bufadienolides in three traditional Chinese medicinal preparations of ChanSu by HPLC-DAD. Nat Prod Comm 4:179-184.
9. Ma XC, Zheng J, Guo DA. (2007b). Highly selective isomerization and dehydrogenation of three major bufadienolides at 3-OH by Fusarium solani. Enz Microb Tech 40:1585-1591.
10. Morishita S, Shoji M, Oguni Y. (1992). Pharmacological actions of Kyushi, a drug containing toad venom: Cardiotonic and arrhythmogenic sffects. Am J Chin Med 20:245.
11. National Commission of Chinese Pharmacopoeia. (2005). Pharmacopoeia of the People's Republic of China. Beijing: Chemical Industry Press. Vol.2, p. 316.
12. Nogawa T, Kamano Y, Yamashita A, Pettit PT. (2001). Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Chan Su. J Nat Prod 64:1148-1152.
13. Steyn PS, Heerden FR. (1998). Bufadienolides of plant and animal origin. Nat Prod Rep 15:397-403.
14. Sun JH, Yang M, Wang BR, Ma XC, Liu P, Guo DA. (2007). Profiling the metabolic difference of seven tanshionones using high-performance with data-dependent acquistion. Rapid Comm Mass Spectrom 21:2211-2226.
15. Toma S, Morishita S, Kuronuma K, Mishima Y, Kawakami M. (1987). Metabolism and pharmacokinetics of cinobufagin. Xenobiotica 17:1195-1202.
16. Urlacher V, Schmid RD. (2002). Biotransformations using prokaryotic P450 monooxygenase. Curr Opin Biotech 13:557-564.
17. Xin XL, Ma XC, Liu KX and Guo DA. (2009). Structural determination of two novel bufadienolides transformed from bufotalin with Alternaria alternate. J Asian Nat Prod Res 11:7-11.
18. Xu W, Luo H, Zhang YP, Shan L, Li HY, Yang M, Liu RH, Zhang WD. (2007). Simultaneous determination of five main active bufadienolides of Chansu in rat plasma by liquid chromatography tandem mass spectrometry. J Chromatograph B 859:157-163.
19. Yang XW, Xing ZT, Cui JR, Fan YL, Zhao R, Li XG. (2001). Studies on the metabolism of cinbifagin and cinbufotalin by human intestinal bacteria. J Peking Univ (Hlth Sci) 33:199-204.
20. Ye M, Qu G, Guo H, Guo D. (2004). Novel cytotoxic bufadienolides derived from bufalin by microbial hydroxylation and their structure-activity relationships. J Steroid Biochem Mol Biol 91:87-98.
21. Zhang LS. (1991a). Desacetylation of cinobufagin by rat liver. Drug Metab Disposit 20:52-55.
22. Zhang LS, Yoshida T, Aoki K, Kuroiwa Y. (1991b). Metabolism of cinobufagin in rat liver microsomes. Identification of epimerized and desacetylated metabolites by liquid chromatography/mass spectrum. Drug Metab Disposit 19: 917-919.
23. Zhang Y, Tang X, Liu XL, Lin X. (2008). Simultaneous determination of three bufadienolides in rat plasma after intravenous administration of bufadienolides extract by ultra performance liquid chromatography electrospray ionization tandem mass spectrometry. Analyt Chim Acta 610:224-231.
24. Zhao YP, Luo XP, Ming YP, Li YM. (2006). Simultaneous determination of three bufadienolides in rat plasma after intravenous administration of bufadienolides extract by ultra performance liquid chromatography electrospray ionization tandem mass spectrometry. J Pharmaceut Biomed Anal 41: 124-128